BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:27 PM
 | 
Sep 20, 2007
 |  BC Extra  |  Clinical News

Wyeth discontinues LXR-623

Karo Bio (SSE:KARO) said partner Wyeth (WYE) discontinued development of LXR-623, a small molecule targeting the liver X receptor (LXR) that was in Phase I testing to treat atherosclerosis. KARO said that although the compound showed efficacy on...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >